Scientific article
English

Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions

Published in

Handbook of experimental pharmacology, vol. 224, p. 455-482

Publication date

2015

Abstract

The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events. In particular, HDL cholesterol levels were shown to be inversely and independently associated with the risk of acute CV diseases in different patient populations, including autoimmune and chronic inflammatory disorders. Some relevant and direct anti-inflammatory activities of HDL have been also recently identified targeting both immune and vascular cell subsets. These studies recently highlighted the improvement of HDL function (instead of circulating levels) as a promising treatment strategy to reduce inflammation and associated CV risk in several diseases, such as systemic lupus erythematosus and rheumatoid arthritis. In these diseases, anti-inflammatory treatments targeting HDL function might improve both disease activity and CV risk. In this narrative review, we will focus on the pathophysiological relevance of HDL and apoA-I levels/functions in different acute and chronic inflammatory pathophysiological conditions.

Citation (ISO format)

MONTECUCCO, Fabrizio et al. Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions. In: Handbook of experimental pharmacology, 2015, vol. 224, p. 455–482. doi: 10.1007/978-3-319-09665-0_14

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0171-2004
684views
0downloads

Technical informations

Creation

02/03/2015 14:59:00

First validation

02/03/2015 14:59:00

Update

23/01/2025 11:37:00

Status update

23/01/2025 11:37:00

Last indexation

23/01/2025 11:44:57
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated